Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))

Marcello Albanesi; David A. Mancardi; Lynn E. Macdonald; Bruno Iannascoli; Laurence Zitvogel; Andrew J. Murphy; Marc Daëron; Jeanette H. Leusen; Pierre Bruhns

doi:10.4049/jimmunol.1290083

Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))

Marcello Albanesi, David A. Mancardi, Lynn E. Macdonald, Bruno Iannascoli, Laurence Zitvogel, Andrew J. Murphy, Marc Daëron, Jeanette H. Leusen, Pierre Bruhns

Résultats de recherche: Contribution à un journal › !!Comment/debate

langue originale	Anglais
Pages (de - à)	1381
Nombre de pages	1
journal	Journal of Immunology
Volume	190
Numéro de publication	3
Les DOIs	https://doi.org/10.4049/jimmunol.1290083
état	Publié - 1 févr. 2013
Modification externe	Oui

Accès au document

10.4049/jimmunol.1290083

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Albanesi, M., Mancardi, D. A., Macdonald, L. E., Iannascoli, B., Zitvogel, L., Murphy, A. J., Daëron, M., Leusen, J. H., & Bruhns, P. (2013). Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517)). Journal of Immunology, 190(3), 1381. https://doi.org/10.4049/jimmunol.1290083

@article{838dd16f7d184d63816be4ab10d67fd5,

title = "Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))",

author = "Marcello Albanesi and Mancardi, {David A.} and Macdonald, {Lynn E.} and Bruno Iannascoli and Laurence Zitvogel and Murphy, {Andrew J.} and Marc Da{\"e}ron and Leusen, {Jeanette H.} and Pierre Bruhns",

year = "2013",

month = feb,

day = "1",

doi = "10.4049/jimmunol.1290083",

language = "English",

volume = "190",

pages = "1381",

journal = "Journal of Immunology",

issn = "0022-1767",

number = "3",

}

Albanesi, M, Mancardi, DA, Macdonald, LE, Iannascoli, B, Zitvogel, L, Murphy, AJ, Daëron, M, Leusen, JH & Bruhns, P 2013, 'Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))', Journal of Immunology, VOL. 190, Numéro 3, p. 1381. https://doi.org/10.4049/jimmunol.1290083

Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517)). / Albanesi, Marcello; Mancardi, David A.; Macdonald, Lynn E. et al.
Dans: Journal of Immunology, Vol 190, Numéro 3, 01.02.2013, p. 1381.

Résultats de recherche: Contribution à un journal › !!Comment/debate

TY - JOUR

T1 - Erratum

T2 - Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517))

AU - Albanesi, Marcello

AU - Mancardi, David A.

AU - Macdonald, Lynn E.

AU - Iannascoli, Bruno

AU - Zitvogel, Laurence

AU - Murphy, Andrew J.

AU - Daëron, Marc

AU - Leusen, Jeanette H.

AU - Bruhns, Pierre

PY - 2013/2/1

Y1 - 2013/2/1

UR - http://www.scopus.com/inward/record.url?scp=84872692876&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1290083

DO - 10.4049/jimmunol.1290083

M3 - Comment/debate

AN - SCOPUS:84872692876

SN - 0022-1767

VL - 190

SP - 1381

JO - Journal of Immunology

JF - Journal of Immunology

IS - 3

ER -

Albanesi M, Mancardi DA, Macdonald LE, Iannascoli B, Zitvogel L, Murphy AJ et al. Erratum: Cutting Edge: FcgRIII (CD16) and FcgRI (CD64) are responsible for anti-glycoprotein 75 monoclonal antibody TA99 therapy for experimental metastatic B16 melanoma (The Journal of Immunology (2012) 189 (5513-5517)). Journal of Immunology. 2013 févr. 1;190(3):1381. doi: 10.4049/jimmunol.1290083